Pedro Miguel Lacal (Pedro M Lacal)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 7

Top Venues

Cancers

International journal of molecular sciences

Nutrients

Istituto Dermopatico dell'Immacolata Istituto di Ricovero e Cura a Carattere Scientifico

Università degli Studi di Roma Tor Vergata Facoltà di Medicina e Chirurgia (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Istituto Dermopatico dell'Immacolata Istituto di Ricovero e Cura a Carattere Scientifico

Italy

Assistant Biologist :: Laboratory of Pharmacology/Laboratory of Molecular Oncology

Istituto Dermopatico dell'Immacolata Istituto di Ricovero e Cura a Carattere Scientifico

Italy

Post-doctoral fellow :: Laboratory of Pharmacology

Università degli Studi di Roma Tor Vergata Facoltà di Medicina e Chirurgia

Italy

Post-doctoral fellow :: Experimental Medicine and Biochemical Sciences Department

National Institutes of Health

United States

Post-doctoral fellow :: Laboratory of Cellular and Developmental Oncology, National Institute of Dental Research

Education History

Università degli Studi di Roma Tor Vergata Facoltà di Medicina e Chirurgia

Italy

PHD

Universidad Autonoma de Madrid Facultad de Ciencias

Spain

PHD

Publications

Maria Grazia Atzori, Claudia Ceci, Federica Ruffini, Scimeca Manuel, Rosella Cicconi, Maurizio Mattei, Pedro Miguel Lacal, Grazia Graziani
The Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) D16F7 Monoclonal Antibody Inhibits Melanoma Adhesion to Soluble VEGFR-1 and Tissue Invasion in Response to Placenta Growth Factor. Cancers 14 (22) (2022)
Lauretta Levati, Cristian Bassi, Simona Mastroeni, Laura Lupini, Gian Carlo Antonini Cappellini, Laura Bonmassar, Ester Alvino, Simona Caporali, Pedro Miguel Lacal, Maria Grazia Narducci, Ivan Molineris, Federica De Galitiis, Massimo Negrini, Giandomenico Russo, Stefania D'Atri
Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy. Cancers 14 (15) (2022)
Grazia Raffaella Tundo, Diego Sbardella, Francesco Oddone, Anna A Kudriaeva, Pedro Miguel Lacal, Alexey A Belogurov, Grazia Graziani, Stefano Marini
At the Cutting Edge against Cancer: A Perspective on Immunoproteasome and Immune Checkpoints Modulation as a Potential Therapeutic Intervention. Cancers 13 (19) (2021)
Marta Chiavari, Gabriella Maria Pia Ciotti, Francesco Canonico, Fabio Altieri, Pedro Miguel Lacal, Grazia Graziani, Pierluigi Navarra, Lucia Lisi
PDIA3 Expression in Glioblastoma Modulates Macrophage/Microglia Pro-Tumor Activation. International journal of molecular sciences 21 (21) (2020)
Maria Luigia Carbone, Pedro Miguel Lacal, Serena Messinese, Laura De Giglio, Carlo Pozzilli, Severino Persechino, Cinzia Mazzanti, Cristina Maria Failla, Gianluca Pagnanelli
Multiple Sclerosis Treatment and Melanoma Development. International journal of molecular sciences 21 (8) (2020)
Claudia Ceci, Maria Grazia Atzori, Pedro Miguel Lacal, Grazia Graziani
Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma. Cancers 12 (11) (2020)
Claudia Ceci, Pedro Miguel Lacal, Lucio Tentori, Maria Gabriella De Martino, Roberto Miano, Grazia Graziani
Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid. Nutrients 10 (11) (2018)

Pedro Miguel Lacal.css-eqlu8i{font-size:small;padding-left:4px;} (Pedro M Lacal)

Publication Activity (10 Years)

Top Topics

Top Venues

Pedro Miguel Lacal (Pedro M Lacal)